Literature DB >> 15994429

Interferon-gamma-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target.

Nisreen El-Hashemite1, David J Kwiatkowski.   

Abstract

Pulmonary lymphangioleiomyomatosis (LAM) and renal angiomyolipoma (AML) are proliferative lesions that occur in sporadic patients, and at much higher frequency in patients with tuberous sclerosis (TSC). The TSC1 and TSC2 genes play a critical role in their pathogenesis. Here we report a marked decrease in interferon (IFN)-gamma expression in both sporadic and TSC-associated AML and LAM. A marked increase in Stat1 expression and phosphorylation at Ser 727, and in phospho-Tyr705-Stat3 levels, was also seen in both AML and LAM tissues. Our results demonstrate that the IFN-gamma-Jak-Stat pathway is perturbed in TSC-related and sporadic LAM and AML, and suggest that IFN-gamma has potential therapeutic benefit for treatment of those lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994429      PMCID: PMC2715313          DOI: 10.1165/rcmb.2005-0152RC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  18 in total

1.  Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

Authors:  Heidi L Kenerson; Lauri D Aicher; Lawrence D True; Raymond S Yeung
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

2.  Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.

Authors:  D N Franz; A Brody; C Meyer; J Leonard; G Chuck; S Dabora; G Sethuraman; T V Colby; D J Kwiatkowski; F X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

3.  Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.

Authors:  J Moss; N A Avila; P M Barnes; R A Litzenberger; J Bechtle; P G Brooks; C J Hedin; S Hunsberger; A S Kristof
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

Review 4.  Lymphangioleiomyomatosis: a review of the literature.

Authors:  E Hancock; J Osborne
Journal:  Respir Med       Date:  2002-01       Impact factor: 3.415

Review 5.  Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling.

Authors:  Chilakamarti V Ramana; M Pilar Gil; Robert D Schreiber; George R Stark
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

6.  Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Andrew Eszterhas; Deborah S Hunter; Marilyn K Glassberg; Raymond S Yeung; Cheryl L Walker; Daniel Noonan; David J Kwiatkowski; Margaret M Chou; Reynold A Panettieri; Vera P Krymskaya
Journal:  J Biol Chem       Date:  2002-06-03       Impact factor: 5.157

Review 7.  Molecular genetic advances in tuberous sclerosis.

Authors:  J P Cheadle; M P Reeve; J R Sampson; D J Kwiatkowski
Journal:  Hum Genet       Date:  2000-08       Impact factor: 4.132

8.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.

Authors:  David J Kwiatkowski; Hongbing Zhang; Jennifer L Bandura; Kristina M Heiberger; Michael Glogauer; Nisreen el-Hashemite; Hiroaki Onda
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

9.  Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

Authors:  Laifong Lee; Paul Sudentas; Brian Donohue; Kirsten Asrican; Aelaf Worku; Victoria Walker; Yanping Sun; Karl Schmidt; Mitchell S Albert; Nisreen El-Hashemite; Alan S Lader; Hiroaki Onda; Hongbing Zhang; David J Kwiatkowski; Sandra L Dabora
Journal:  Genes Chromosomes Cancer       Date:  2005-03       Impact factor: 5.006

10.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Authors:  Andrew R Tee; Diane C Fingar; Brendan D Manning; David J Kwiatkowski; Lewis C Cantley; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

View more
  17 in total

Review 1.  α-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions.

Authors:  Diane C Chugani
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.

Authors:  Vera P Krymskaya; Francis X McCormack
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

3.  Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.

Authors:  Wendy K Steagall; Mario Stylianou; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  JCI Insight       Date:  2019-03-07

Review 4.  Optimizing treatments for lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Rev Respir Med       Date:  2012-06       Impact factor: 3.772

Review 5.  Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.

Authors:  Stephen C Juvet; Francis X McCormack; David J Kwiatkowski; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-10       Impact factor: 6.914

6.  Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis.

Authors:  Yasuhiro Terasaki; Kinnosuke Yahiro; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Mario P Stylianou; Jilly F Evans; Ameae M Walker; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2010-04-22       Impact factor: 21.405

7.  Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.

Authors:  Elena A Goncharova; Dmitry A Goncharov; Gautam Damera; Omar Tliba; Yassine Amrani; Reynold A Panettieri; Vera P Krymskaya
Journal:  Mol Pharmacol       Date:  2009-07-13       Impact factor: 4.436

8.  Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis.

Authors:  Julio C Valencia; Gustavo Pacheco-Rodriguez; Adriana K Carmona; Janina Xavier; Patrick Bruneval; William K Riemenschneider; Yoshihiko Ikeda; Zu-Xi Yu; Victor J Ferrans; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2006-02-10       Impact factor: 6.914

Review 9.  Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Stephen R Hammes; Vera P Krymskaya
Journal:  Horm Cancer       Date:  2012-11-27       Impact factor: 3.869

10.  Inactivation of mammalian target of rapamycin increases STAT1 nuclear content and transcriptional activity in alpha4- and protein phosphatase 2A-dependent fashion.

Authors:  Jill A Fielhaber; Ying-Shan Han; Jason Tan; Shuo Xing; Catherine M Biggs; Kwang-Bo Joung; Arnold S Kristof
Journal:  J Biol Chem       Date:  2009-06-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.